Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder

Neuropsychopharmacology

Volumn 37, Issue 10, 2012, Pages 2222-2232

  Faria, Vanda ^a   Appel, Lieuwe ^b   Åhs, Fredrik ^c   Linnman, Clas ^d   Pissiota, Anna ^a   Frans, Örjan ^a   Bani, Massimo ^e   Bettica, Paolo ^e   Pich, Emilio M ^e,f   Jacobsson, Eva ^b   Wahlstedt, Kurt ^b   Fredrikson, Mats ^a   Furmark, Tomas ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c DUKE UNIVERSITY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e GSK   (Italy)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

amygdala; PET; placebo; SAD; SSRIs; subregions

Indexed keywords

CITALOPRAM; PAROXETINE; PLACEBO; WATER O 15;

ADULT; AMYGDALOID NUCLEUS; ANXIETY; ARTICLE; BRAIN BLOOD FLOW; CLINICAL GLOBAL IMPRESSION SCALE; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLACEBO EFFECT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUBLIC SPEAKING; SOCIAL PHOBIA; TASK PERFORMANCE; TREATMENT RESPONSE;

ADULT; AMYGDALA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOBIC DISORDERS; PLACEBO EFFECT; POSITRON-EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGIONAL BLOOD FLOW; SEROTONIN UPTAKE INHIBITORS;

EID: 84865211436     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.72     Document Type: Article

References (84)

1. Aggleton JP (1985). A description of intra-amygdaloid connections in old world monkeys. Exp Brain Res 57: 390-399. (Pubitemid 15198708)
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders (DSM IV) 4th edn American Psychiatric Press: Washington, DC.
3. Bach DR, Behrens TE, Garrido L, Weiskopf N, Dolan RJ (2011). Deep and superficial amygdala nuclei projections revealed in vivo by probabilistic tractography. J Neurosci 31: 618-623.
4. Bar M (2009). A cognitive neuroscience hypothesis of mood and depression. Trends Cogn Sci 13: 456-463.
5. Benedetti F, Arduino C, Costa S, Vighetti S, Tarenzi L, Rainero I et al (2006). Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain 121: 133-144. (Pubitemid 43261640)
6. Benedetti F, Colloca L, Torre E, Lanotte M, Melcarne A, Pesare M et al (2004). Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci 7: 587-588. (Pubitemid 38691896)
7. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK (2005). Neurobiological mechanisms of the placebo effect. J Neurosci 25: 10390-10402. (Pubitemid 41628443)
8. Bigos KL, Pollock BG, Aizenstein HJ, Fisher PM, Bies RR, Hariri AR (2008). Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology 33: 3221-3225.
9. Britton JC, Phan KL, Taylor SF, Fig LM, Liberzon I (2005). Corticolimbic blood flow in posttraumatic stress disorder during script-driven imagery. Biol Psychiatry 57: 832-840. (Pubitemid 40488351)
10. Bueno CH, Zangrossi H, Viana MB (2005). The inactivation of the basolateral nucleus of the rat amygdala has an anxiolytic effect in the elevated T-maze and light/dark transition tests. Braz J Med Biol Res 38: 1697-1701. (Pubitemid 41671758)
11. Cheng L-L, Wang S-J, Gean P-W (1998). Serotonin depresses excitatory synaptic transmission and depolarization-evoked Ca2+ influx in rat basolateral amygdala via 5-HT1A receptors. Eur J Neurosci 10: 2163-2172.
12. Colloca L, Lopiano L, Lanotte M, Benedetti F (2004). Overt vs covert treatment for pain, anxiety and Parkinson's disease. Lancet Neurol 3: 679-684. (Pubitemid 39370638)
13. Colloca L, Miller FG (2011). Role of expectations in health. Curr Opin Psychiatry 24: 149-155.
14. Cooney RE, Joormann J, Eugène F, Dennis EL, Gotlib IH (2010). Neural correlates of rumination in depression. Cogn Affect Behav Neurosci 10: 470-478.
15. Davidson JRT (2006). Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry 67: 20-26. (Pubitemid 44836357)
16. Davis FC, Johnstone T, Mazzulla EC, Oler JA, Whalen PJ (2010). Regional response differences across the human amygdaloid complex during social conditioning. Cereb Cortex 20: 612-621.
17. Domschke K, Dannlowski U (2009). Imaging genetics of anxiety disorders. NeuroImage 15: 822-831.
18. Eippert F, Finsterbusch J, Bingel U, Büchel C (2009). Direct evidence for spinal cord involvement in placebo analgesia. Science 16: 404.
19. Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD (2009). Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Arch Gen Psychiatry 6: 1361-1372.
20. Evans KC, Dougherty DD, Pollack MH, Rauch SL (2006). Using neuroimaging to predict treatment response in mood and anxiety disorders. Ann Clin Psychiatry 18: 33-42.
21. Faria V, Fredrikson M, Furmark T (2008). Imaging the placebo response: a neurofunctional review. Eur Neuropsychopharmacol 18: 473-485.
22. First M, Gibbon M, Spitzer R, Williams J (1998). SCID-I: Interview Protocol (in Swedish). Pilgrim Press: Stockholm.
23. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC et al (2010). Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303: 47-53.
24. François C, Despiégel N, Maman K, Saragoussi D, Auquier P (2010). Anxiety disorders, major depressive disorder and the dynamic relationship between these conditions: treatment patterns and cost analysis. J Med Econ 13: 99-109.
25. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF (2000). Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: A survey of current 'next-step' practices. J Clin Psychiatry 61: 403-408. (Pubitemid 30452205)
26. Fuente-Fernández R de la, Schulzer M, Stoessl AJ (2004). Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry 56: 67-71. (Pubitemid 38844781)
27. Furmark T, Appel L, Henningsson S, Åhs F, Faria V, Linnman C et al (2008). A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci 28: 13066-13074.
28. Furmark T, Appel L, Michelgård A, Wahlstedt K, Åhs F, Zancan S et al (2005). Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58: 132-142. (Pubitemid 41008130)
29. Furmark T, Henningsson S, Appel L, Åhs F, Linnman C, Pissiota A et al (2009). Genotype over-diagnosis in amygdala responsiveness: affective processing in social anxiety disorder. J Psychiatry Neurosci 34: 30-40.
30. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Långström B et al (2002). Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 59: 425-433. (Pubitemid 34477677)
31. Goldin PR, McRae K, Ramel W, Gross JJ (2008). The neural bases of emotion regulation: reappraisal and suppression of negative emotion. Biol Psychiatry 63: 577-586. (Pubitemid 351273191)
32. Green S, Vale AL (1992). Role of amygdaloid nuclei in the anxiolytic effects of benzodiazepines in rats. Behav Pharmacol 3: 261-264.
33. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM (2006). Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 59: 816-820.
34. Inoue T, Li XB, Abekawa T, Kitaichi Y, Izumi T, Nakagawa S et al (2004). Selective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdala. Eur J Pharmacol 497: 311-316. (Pubitemid 39164896)
35. Izumi T, Inoue T, Kitaichi Y, Nakagawa S, Koyama T (2006). Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor. Eur J Psychopharmacol 534: 129-132. (Pubitemid 43384193)
36. Kessler RC (2003). The impairments caused by social phobia in the general population: implications for intervention. Acta Psychiatr Scand 108: 19-27.
37. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSMIV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617-627. (Pubitemid 40973437)
38. Khan A, Bhat A (2008). Is the problem of a high placebo response unique to antidepressant trials? J Clin Psychiatry 69: 1979-1980.
39. Khan A, Leventhal RM, Khan SR, Brown WA (2002). Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 22: 40-45. (Pubitemid 34101291)
40. Kilts CD, Kelsey JE, Knight B, Ely TD, Bowman FD, Gross RE et al (2006). The neural correlates of social anxiety disorder and response to pharmacotherapy. Neuropsychopharmacology 31: 2243-2253. (Pubitemid 44413202)
41. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5: e45.
42. Kirsch I, Sapirstein G (1998). Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prev Treat 6: 1-16.
43. Krummenacher P, Candia V, Folkers G, Schedlowski M, Schönbä chler G (2010). Prefrontal cortex modulates placebo analgesia. Pain 48: 368-374.
44. Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L et al (2000). Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 10: 120-131. (Pubitemid 30456920)
45. Lázaro-Muñoz G, LeDoux JE, Cain CK (2010). Sidman instrumental avoidance initially depends on lateral and basal amygdala and is constrained by central amygdala-mediated Pavlovian processes. Biol Psychiatry 67: 1120-1127.
46. LeDoux J (2007). The Amygdala. Curr Biol 17: R868-R874.
47. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M (2002). Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 159: 122-129. (Pubitemid 41070737)
48. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ et al (2010). Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 67: 857-865.
49. Liebowitz MR (1987). Social phobia. Mod Probl Pharmacopsychiatry 22: 141-173.
50. Mai JK, Assheuer J, Paxinos G (2004). Atlas of the Human Brain. Elsevier Academic: San Diego.
51. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH (2003). An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. NeuroImage 19: 1233-1239. (Pubitemid 36918259)
52. Maslowsky J, Mogg K, Bradley BP, McClure-Tone E, Ernst M, Pine DS et al (2010). A preliminary investigation of neural correlates of treatment in adolescents with generalized anxiety disorder. J Child Adol Psychopharmacol 20: 105-111.
53. Mathew SJ, Price RB, Charney DS (2008). Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genetics 148: 89-98. (Pubitemid 351705126)
54. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S et al (2002). The functional neuroanatomy of the placebo effect. Am J Psychiatry 159: 728-737. (Pubitemid 34465045)
55. Moncrieff J, Wessely S, Hardy R (2004). Active placebos vs antidepressants for depression. Cochrane Database Syst Rev 1: CD003012.
56. Morris JS, Buchel C, Dolan RJ (2001). Parallel neural responses in amygdala subregions and sensory cortex during implicit fear conditioning. NeuroImage 13: 1044-1052. (Pubitemid 32553535)
57. Murphy SE, Norbury R, Sullivan UO, Cowen PJ, Harmer CJ (2009). Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry 194: 535-540.
58. Niehoff DL, Kuhar MJ (1983). Benzodiazepine receptors: localization in rat amygdala. J Neurosci 3: 2091-2097.
59. Ochsner KN, Gross JJ (2005). The cognitive control of emotion. Trends Cogn Sci 9: 242-249. (Pubitemid 40615112)
60. Pazos A, Probst A, Palacios JM (1987). Serotonin receptors in the human brain-III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 21: 97-122. (Pubitemid 17076866)
61. Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K, Ingvar M (2005). Placebo in emotional processing-induced expectations of anxiety relief activate a generalized modulatory network. Neuron 46: 957-969. (Pubitemid 40805354)
62. Petrovic P, Kalso E, Petersson KM, Ingvar M (2002). Placebo and opioid analgesia. Imaging a shared neuronal network. Science 295: 1737-1740.
63. Phan KL, Britton JC, Taylor SF, Fig LM, Liberzon I (2006). Corticolimbic blood flow during nontraumatic emotional processing in posttraumatic stress disorder. Arch Gen Psychiatry 63: 184-192. (Pubitemid 43213880)
64. Phelps EA, LeDoux JE (2005). Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 48: 175-187. (Pubitemid 41476352)
65. Pitkänen A, Savander V, LeDoux JE (1997). Organization of intraamygdaloid circuitries in the rat: an emerging framework for understanding functions of the amygdala. Trends Neurosci 20: 517-523. (Pubitemid 27459657)
66. Ravindran LN, Stein MB (2010). The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 71: 839-854.
67. Ressler KJ (2010). Amygdala activity, fear, and anxiety: modulation by stress. Biol Psychiatry 67: 1117-1119.
68. Rosen HJ, Levenson RW (2009). The emotional brain: combining insights from patients and basic science. Neurocase 15: 173-181.
69. Rourke HO, Fudge JL (2006). Distribution of serotonin transporter labeled fibers in distribution of serotonin transporter labeled fibers in amygdaloid subregions: implications for mood disorders. Biol Psychiatry 60: 479-490. (Pubitemid 44292152)
70. Roy AK, Shehzad Z, Marqulies DS, Kelly AM, Uddin LQ, Gotimer K et al (2010). Functional connectivity of the human amygdala using resting state fMRI. NeuroImage 45: 614-626.
71. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK (2007). Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 55: 325-336. (Pubitemid 47048908)
72. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59: 22-33. (Pubitemid 29001829)
73. Shin LM, Liberzon I (2010). The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacol 35: 169-191.
74. Spielberger CD, Gorsuch RL, Lushene RE (1970). Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press: Palo Alto, CA.
75. Straube T, Glauer M, Dilger S, Mentzel H-J, Miltner WHR (2006). Effects of cognitive-behavioral therapy on brain activation in specific phobia. NeuroImage 29: 125-135. (Pubitemid 41828037)
76. Stutzmann GE, McEwen BS, LeDoux JE (1998). Serotonin modulation of sensory inputs to the lateral amygdala: dependency on corticosterone. J Neurosci 18: 9529-9538. (Pubitemid 28512481)
77. Talairach J, Tournoux P (1988). Co-Planar Stereotaxic Atlas of the Human Brain. Georg Thiene Verlag: Stuttgart, Germany.
78. Telles-Correia D, Guerreiro DF, Oliveira S, Figueira ML (2007). Differences between SSRI's pharmacokinetics and pharmacodynamics. Acta Med Port 20: 167-174.
79. Tye KM, Prakash R, Kim S-Y, Fenno LE, Grosenick L, Zarabi H et al (2011). Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 471: 358-362.
80. Uhlenhuth EH, Matuzas W, Warner TD, Thompson PM (1997). Growing placebo response rate: the problem in recent therapeutic trials? Psychopharmacol Bull 33: 31-39. (Pubitemid 27184192)
81. Van Ameringen M, Mancini C, Farvolden P, Oakman J (2000). Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. Expert Opin Investig Drugs 9: 2215-2231.
82. Yonkers KA, Dyck IR, Keller MB (2001). An eight-year longitudinal comparison of clinical course and characteristics of social phobia among men and women. Psychiatric Services 52: 637-643. (Pubitemid 32429293)
83. Zaider TI, Heimberg RG, Fresco DM, Scheiner FR, Liebowitz MR (2003). Evaluation of the clinical global impression scale among individuals with social anxiety disorder. Psychol Med 33: 611-622. (Pubitemid 36626043)
84. Zubieta JK, Stohler CS (2009). Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci 1156: 198-210.